Extracorporeal CO2 Removal Devices

Extracorporeal CO2 Removal Devices Market Outlook

The global Extracorporeal CO2 Removal Devices market is projected to reach USD 1.5 billion by 2035, growing at a CAGR of 8.2% during the forecast period from 2025 to 2035. This growth is driven by the increasing prevalence of respiratory diseases such as Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD), which necessitate advanced medical interventions. Additionally, the rising aging population and subsequent demand for innovative healthcare solutions contribute significantly to market expansion. Moreover, advancements in healthcare technology and increased investments in research and development are expected to further bolster the demand for extracorporeal CO2 removal devices. The growing awareness of the benefits of these devices among healthcare providers and patients alike is creating a conducive environment for market growth.

Growth Factor of the Market

The growth of the Extracorporeal CO2 Removal Devices market is primarily fueled by factors such as the rising incidence of respiratory disorders, which elevate the need for effective and rapid CO2 removal solutions. As the healthcare landscape evolves, there is a marked shift towards minimally invasive procedures, increasing the demand for devices that support extracorporeal carbon dioxide removal. Furthermore, the ongoing globalization and urbanization trends are leading to an increase in air pollution, exacerbating respiratory health issues and thereby driving the market for CO2 removal devices. Enhanced healthcare expenditure, particularly in developing regions, is also expected to play a significant role in boosting market growth. Advances in technology, including the development of more efficient and safer devices, continue to encourage market expansion and attract investments from various stakeholders.

Key Highlights of the Market

• The market is expected to grow at a CAGR of 8.2% from 2025 to 2035.
• North America is anticipated to hold the largest market share due to advanced healthcare infrastructure.
• Increased prevalence of diseases like ARDS and COPD is driving demand.
• Technological advancements are leading to the development of innovative devices.
• Growing awareness and training among healthcare professionals regarding the use of these devices.

By Product Type

Membrane Oxygenators:

Membrane oxygenators are increasingly becoming a popular choice in the Extracorporeal CO2 Removal Devices market due to their ability to facilitate efficient gas exchange. These devices utilize semi-permeable membranes to separate blood from gas, allowing for the removal of carbon dioxide while oxygenation occurs simultaneously. The growing preference for membrane oxygenators can be attributed to their superior performance characteristics, which include reduced blood trauma and improved biocompatibility compared to traditional methods. Moreover, the integration of advanced materials in membrane design has led to enhanced gas transfer efficiency, making them suitable for critically ill patients. As healthcare facilities continue to emphasize the importance of patient safety and comfort, membrane oxygenators are expected to play a dominant role in the market landscape.

Hollow Fiber Oxygenators:

Hollow fiber oxygenators are another significant segment in the Extracorporeal CO2 Removal Devices market, owing to their unique design that maximizes surface area for gas exchange. These devices consist of thousands of small, hollow fibers that increase the area available for diffusion, allowing for efficient CO2 removal and oxygenation. The demand for hollow fiber oxygenators is bolstered by their ability to handle high blood flow rates, making them suitable for use in both emergency and elective procedures. Additionally, advancements in fiber technology and manufacturing processes are enhancing the performance and reliability of these devices, thereby increasing their adoption in clinical settings. Healthcare professionals favor hollow fiber oxygenators for their efficiency and ease of use, which is expected to continue driving growth in this segment.

Pump Oxygenators:

Pump oxygenators represent a crucial segment of the Extracorporeal CO2 Removal Devices market, especially in scenarios requiring controlled blood circulation and gas exchange. These devices utilize mechanical pumps to facilitate the movement of blood through the oxygenator, ensuring adequate perfusion and gas exchange even in critically ill patients. The growing prevalence of cardiovascular diseases and the need for surgical interventions are driving the demand for pump oxygenators. Innovations in pump technology are leading to the development of more compact, efficient, and reliable devices, which are essential for operating rooms and intensive care units. As healthcare systems continue to evolve and respond to the increasing burden of chronic diseases, the importance of pump oxygenators in managing patient care will likely grow.

Others:

The 'Others' category encompasses a range of extracorporeal CO2 removal devices not classified under the main types. This segment includes emerging technologies and hybrid devices that combine various functionalities to enhance patient care. Innovations in this category are often driven by the need for customization and adaptability in diverse clinical environments. As healthcare providers look for solutions that can cater to specific patient needs, the demand for these unique devices is expected to rise. Furthermore, ongoing research and development efforts in this segment aim to produce devices that offer advanced features such as portability and user-friendly interfaces. As a result, the 'Others' category is anticipated to witness steady growth, contributing to the overall expansion of the market.

By Application

Acute Respiratory Distress Syndrome:

Acute Respiratory Distress Syndrome (ARDS) is a major application area for extracorporeal CO2 removal devices, as the condition is characterized by severe respiratory failure and high levels of carbon dioxide retention in the body. The ability of these devices to efficiently remove CO2 and improve oxygenation makes them vital in managing ARDS patients. With the increasing incidence of ARDS in critically ill patients, driven by factors such as pneumonia, sepsis, and trauma, the demand for CO2 removal devices is on the rise. Furthermore, clinical studies supporting the efficacy of extracorporeal CO2 removal in managing ARDS are reinforcing the adoption of these technologies in hospitals and critical care settings. This segment is expected to see significant growth as healthcare providers continue to seek effective solutions for this challenging condition.

Chronic Obstructive Pulmonary Disease:

Chronic Obstructive Pulmonary Disease (COPD) is another critical application area for extracorporeal CO2 removal devices. COPD patients often experience difficulty in expelling carbon dioxide, leading to hypercapnia and exacerbated respiratory distress. The use of extracorporeal devices to facilitate CO2 removal can significantly enhance the quality of life for these patients and improve their overall respiratory status. As the global prevalence of COPD continues to rise, driven by factors such as smoking and environmental pollution, healthcare providers are increasingly incorporating these devices into treatment protocols. The mounting body of evidence supporting their effectiveness in managing COPD symptoms is expected to foster further growth in this application segment.

Bridge to Transplant:

Extracorporeal CO2 removal devices are also utilized as a 'bridge to transplant' for patients awaiting lung transplantation. In this critical application, the devices provide essential respiratory support, helping to maintain adequate gas exchange in patients who are too ill to undergo transplantation promptly. The increasing demand for lung transplants, coupled with the shortage of donor organs, has amplified the reliance on extracorporeal technologies to stabilize patients. As transplant centers adopt these devices as part of standard protocols, their role in supporting patients through the waiting period is expected to solidify. This application segment is anticipated to see substantial growth as advancements in technology and procedural protocols enhance the effectiveness of care for transplant candidates.

Others:

The 'Others' category in the application segment includes various conditions that necessitate the use of extracorporeal CO2 removal devices, such as metabolic disorders and specific surgical procedures that require temporary respiratory support. As healthcare evolves, the versatility of these devices allows for their application in a wide range of clinical settings. Ongoing research into new applications demonstrates the potential of these devices to address emerging healthcare challenges. As awareness grows regarding the benefits of CO2 removal technologies, more healthcare facilities are likely to explore their use beyond traditional applications. This segment is expected to gradually expand as clinicians seek innovative solutions for diverse medical needs.

By User

Hospitals:

Hospitals are the primary users of extracorporeal CO2 removal devices, given their extensive application in acute care settings and critical care units. With the increasing patient volume suffering from severe respiratory disorders, hospitals are investing in advanced technologies to improve patient outcomes. The presence of trained healthcare professionals and specialized equipment enables hospitals to effectively utilize these devices for complex medical cases. Additionally, the integration of extracorporeal CO2 removal devices into standardized treatment protocols enhances their routine use in hospitals. As patient acuity levels rise, the demand for these devices in hospital settings is expected to grow steadily, reflecting the ongoing evolution of critical care medicine.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are also emerging as significant users of extracorporeal CO2 removal devices, particularly for outpatient procedures that necessitate short-term respiratory support. The shift towards outpatient care and minimally invasive techniques is driving the adoption of these devices in ASCs. The ability to provide effective gas exchange and manage CO2 levels in a controlled environment aligns with the goals of ASCs to enhance patient safety and recovery. As advancements in technology make these devices more accessible and easier to use, ASCs are gradually incorporating them into their surgical protocols, contributing to the overall market growth in this user segment.

Specialty Clinics:

Specialty clinics play a crucial role in the Extracorporeal CO2 Removal Devices market by catering to specific patient populations requiring targeted respiratory treatments. These clinics often focus on conditions such as chronic respiratory diseases and post-transplant care, where the use of advanced technologies can significantly improve patient outcomes. The personalized approach adopted by specialty clinics allows for tailored treatment plans that incorporate extracorporeal CO2 removal devices as part of comprehensive care. As awareness of these devices increases and more clinics recognize the benefits of their use, the specialty clinic segment is expected to grow, driven by a commitment to improving respiratory health.

Others:

The 'Others' category in the user segment encompasses various healthcare facilities and settings that utilize extracorporeal CO2 removal devices, including long-term care facilities and rehabilitation centers. These settings are increasingly recognizing the importance of respiratory support technologies in managing patients with chronic respiratory issues. The versatility of these devices allows them to be adapted for use in different care environments, broadening their application scope. As healthcare providers in diverse settings become more educated about the benefits of CO2 removal technologies, the demand from this user segment is likely to rise, enhancing the overall market landscape.

By Modality

Veno-Venous:

The veno-venous modality is a common approach in extracorporeal CO2 removal, primarily employed for patients with respiratory failure. This technique involves the withdrawal of venous blood, its passage through an oxygenator for gas exchange, and subsequent reinfusion into the venous system. The veno-venous approach is particularly beneficial for patients with severe lung diseases, as it helps to maintain oxygen levels while effectively eliminating carbon dioxide. The increasing incidence of respiratory disorders is propelling the demand for veno-venous devices, as they provide critical support in acute settings. As healthcare providers continue to adopt this modality for managing respiratory failure, the veno-venous segment is expected to witness significant growth.

Veno-Arterial:

Veno-arterial (VA) modalities are utilized in more complex cases where both cardiac and respiratory support is required, such as during cardiac surgery or in patients with simultaneous heart and lung failure. This technique draws blood from the venous circulation, oxygenates it, and then reinfuses it directly into the arterial system to restore systemic circulation. The use of VA modalities is growing due to the increasing prevalence of cardiopulmonary diseases and the need for comprehensive support in critically ill patients. The clinical efficacy and versatility of veno-arterial devices make them essential in multidisciplinary care settings, contributing to their rising adoption in the market.

Hybrid:

Hybrid modalities combine elements of both veno-venous and veno-arterial techniques to provide comprehensive support for patients with complex medical conditions. These systems are designed to accommodate varying clinical scenarios, allowing for personalized treatment tailored to the patient's specific needs. The flexibility offered by hybrid devices is increasingly recognized in critical care settings, where patient conditions can rapidly change, necessitating an adaptable approach. As the healthcare landscape evolves, the demand for hybrid modalities is expected to grow, driven by the pursuit of innovative solutions to improve patient outcomes and streamline care delivery.

By Region

The Extracorporeal CO2 Removal Devices market is experiencing varied growth across different regions, with North America holding the largest market share. In 2025, North America is expected to account for approximately 40% of the global market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a growing prevalence of respiratory diseases. The region is also home to major players in the medical devices industry, which fosters innovation and adoption of new technologies. The presence of well-established hospitals and specialized clinics facilitates the integration of extracorporeal CO2 removal devices into routine clinical practice, contributing to the region’s dominance in the market. Furthermore, the CAGR for North America is projected to be around 7.5%, indicating sustained growth over the forecast period.

Europe is also witnessing significant growth in the Extracorporeal CO2 Removal Devices market, accounting for approximately 25% of the total market share in 2025. The region's growth is attributed to the increasing demand for advanced respiratory support systems, driven by high rates of chronic respiratory diseases and an aging population. Additionally, European countries are investing in healthcare infrastructure and developing policies that support the adoption of innovative medical technologies. The burgeoning focus on improving patient outcomes and enhancing healthcare quality is likely to propel the demand for extracorporeal devices across hospitals and specialty clinics. The projected CAGR for the European market is estimated at 6.8%, reflecting the commitment to advancing respiratory care.

Opportunities

One of the most promising opportunities in the Extracorporeal CO2 Removal Devices market lies in technological advancements and innovations. As the healthcare sector continues to evolve, there is a persistent emphasis on developing more efficient, portable, and user-friendly devices capable of meeting the diverse needs of patients and healthcare providers. Companies that invest in research and development to create next-generation technologies will likely capture significant market share. The integration of artificial intelligence and machine learning into these devices to enhance real-time monitoring and decision-making is another area that presents substantial growth potential. By leveraging these advancements, manufacturers can improve patient outcomes while optimizing resource utilization in clinical settings.

Another opportunity stems from the increasing awareness and education surrounding the benefits of extracorporeal CO2 removal devices among healthcare professionals. As more clinicians recognize the efficacy of these devices in managing various respiratory disorders, the demand for training and skills enhancement will grow. This trend opens avenues for collaboration between device manufacturers and healthcare institutions to develop comprehensive training programs, workshops, and simulation-based learning experiences. By investing in education and training initiatives, manufacturers can not only drive device adoption but also improve the overall standard of patient care. Such collaborations could lead to a more substantial market presence and establish long-term relationships within the healthcare ecosystem.

Threats

Despite the growing demand for Extracorporeal CO2 Removal Devices, several threats could impact market growth. One of the most significant challenges is the increasing regulatory scrutiny and stringent approval processes for medical devices. Regulatory bodies are continuously updating their requirements to ensure patient safety and efficacy, which can delay product launches and increase development costs for manufacturers. Companies must invest time and resources to navigate these regulations, which may hinder their ability to innovate or expand their product offerings swiftly. Consequently, this prolonged timeline for approval may limit market opportunities, especially for smaller players lacking the necessary resources to comply with regulatory demands.

Additionally, the presence of alternative therapies poses a considerable threat to the growth of the extracorporeal CO2 removal devices market. Various non-invasive respiratory support options, such as High-Flow Nasal Cannula (HFNC) and Continuous Positive Airway Pressure (CPAP) systems, are gaining traction among healthcare providers. These alternatives can offer effective management of respiratory distress without the need for invasive procedures, thereby posing competition to extracorporeal technologies. As more facilities adopt these options for managing respiratory patients, the demand for invasive devices may experience stagnation. Manufacturers must position their products effectively by emphasizing the unique advantages and clinical benefits of extracorporeal CO2 removal devices to mitigate this threat.

Competitor Outlook

• Medtronic
• Fresenius Medical Care AG & Co. KGaA
• Getinge AB
• Terumo Corporation
• Maquet Holding B.V.
• LifeTech Scientific Corporation
• Nipro Corporation
• Gambro Healthcare
• Cardiovascular Systems, Inc.
• Roche Diagnostics
• HLS Therapeutics Inc.
• Edwards Lifesciences Corporation
• Asahi Kasei Corporation
• Neuroth AG
• Medline Industries, Inc.

The competitive landscape of the Extracorporeal CO2 Removal Devices market is characterized by the presence of several prominent players who are continuously striving to enhance their product offerings and maintain market share. Leading companies are engaging in strategic partnerships, mergers, and acquisitions to expand their product portfolios and strengthen their market presence. Additionally, the focus on research and development is driving innovation within the sector, enabling manufacturers to introduce cutting-edge technologies that cater to the evolving needs of healthcare providers. Companies are also investing in marketing strategies to raise awareness about the benefits of their devices, further intensifying competition within the market.

Medtronic, one of the major players in the market, is well-known for its advanced medical technologies, including extracorporeal CO2 removal solutions. The company’s extensive experience in the healthcare industry, combined with its commitment to innovation, positions it as a leader in providing effective respiratory support. Medtronic is constantly enhancing its product features and integrating new technologies to address the complex needs of critically ill patients. Similarly, Fresenius Medical Care AG & Co. KGaA is recognized for its expertise in renal and respiratory therapies, focusing on the development of high-quality devices that deliver exceptional performance in clinical settings.

Getinge AB is another key player in the Extracorporeal CO2 Removal Devices market, emphasizing sustainability and patient-centric solutions. The company's innovative products are designed to enhance patient safety and optimize clinical workflows while minimizing environmental impact. With a strong emphasis on research and development, Getinge is continuously exploring new technologies to improve patient outcomes and expand its global reach. Additionally, Terumo Corporation, known for its versatile medical devices, is actively involved in promoting extracorporeal CO2 removal technologies. By leveraging its vast distribution network and commitment to innovation, Terumo aims to capture significant market share and enhance its competitive position in the industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Getinge AB
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Neuroth AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Gambro Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Nipro Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Terumo Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Maquet Holding B.V.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 HLS Therapeutics Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Asahi Kasei Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Medline Industries, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Cardiovascular Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 LifeTech Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Edwards Lifesciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Fresenius Medical Care AG & Co. KGaA
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Extracorporeal CO2 Removal Devices Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Ambulatory Surgical Centers
    • 6.1.3 Specialty Clinics
    • 6.1.4 Others
  • 6.2 Extracorporeal CO2 Removal Devices Market, By Modality
    • 6.2.1 Veno-Venous
    • 6.2.2 Veno-Arterial
    • 6.2.3 Hybrid
  • 6.3 Extracorporeal CO2 Removal Devices Market, By Application
    • 6.3.1 Acute Respiratory Distress Syndrome
    • 6.3.2 Chronic Obstructive Pulmonary Disease
    • 6.3.3 Bridge to Transplant
    • 6.3.4 Others
  • 6.4 Extracorporeal CO2 Removal Devices Market, By Product Type
    • 6.4.1 Membrane Oxygenators
    • 6.4.2 Hollow Fiber Oxygenators
    • 6.4.3 Pump Oxygenators
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Extracorporeal CO2 Removal Devices Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Extracorporeal CO2 Removal Devices market is categorized based on

By Product Type

• Membrane Oxygenators
• Hollow Fiber Oxygenators
• Pump Oxygenators
• Others

By Application

• Acute Respiratory Distress Syndrome
• Chronic Obstructive Pulmonary Disease
• Bridge to Transplant
• Others

By User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Modality

• Veno-Venous
• Veno-Arterial
• Hybrid

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic
• Fresenius Medical Care AG & Co. KGaA
• Getinge AB
• Terumo Corporation
• Maquet Holding B.V.
• LifeTech Scientific Corporation
• Nipro Corporation
• Gambro Healthcare
• Cardiovascular Systems, Inc.
• Roche Diagnostics
• HLS Therapeutics Inc.
• Edwards Lifesciences Corporation
• Asahi Kasei Corporation
• Neuroth AG
• Medline Industries, Inc.